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Introduction: Marfan syndrome patients are prone to aortic dilatation, dissection, and rupture. Success of aortic root
replacement has generated a cohort of patients surviving longer and presenting with distal aortic dissection and
enlargement. Thoracic endovascular stent-graft repair (TEVR) is being increasingly utilized to exclude aneurysms
resulting from chronic aortic dissection. This report explores the role of TEVR in Marfan patients with this pathology.
Methods: Review of a prospectively maintained database identified seven patients with Marfan syndrome offered
endovascular repair of aneurysmal chronic aortic dissection. All patients had previous aortic root repair. Talent or Valiant
(Medtronic Vascular, Santa Rosa, Calif) aortic stent-grafts were used to occlude the dissection entry tear and cover the
thoracic aorta. Electronic data, case notes, and radiological surveillance were analyzed.
Results: Seven consecutive patients (six male; mean age, 45.9  10 years, range, 29 to 63) underwent successful thoracic
stent-graft deployment. Mean aortic aneurysmal diameter was 63.4mm (11.2) with six of seven dissections extending
to the aortic bifurcation. No perioperative neurological events occurred. Thirty-day mortality was 1/7 (14%) due to
congestive cardiac failure. At median 16 month follow-up, two of six cases (33%) required intervention for endoleak.
Aortic false lumen thrombosis (FLT) occurred in 5/6 (83%) cases and partial FLT occurred in 1/6 (17%). All thoracic
aortas continued to dilate during follow-up. Crude median aortic growth rate was 7.2 mm/year (range, 3.5 to 19 mm).
Conclusion: TEVR in Marfan syndrome patients with chronic aortic dissection is technically feasible. However, post
intervention surveillance confirms that the aorta continues to dilate despite graft deployment and false lumen thrombosis.
Endovascular repair may offer a viable option in patients who have contraindications to open surgery, but longer follow
up of more patients is required to define the place of this therapy. (J Vasc Surg 2009;50:987-91.)Marfan syndrome is a systemic disorder of connective
tissue caused by mutations in the extracellular matrix pro-
tein fibrillin 1. Aortic aneurysm and dissection remain the
most life-threatening manifestations of this syndrome;1
without intervention, death occurs in early adulthood. The
success of current medical and surgical treatment of Marfan
syndrome has substantially improved the life expectancy in
this patient population.
Aortic root dilatation is a typical vascular lesion in
patients with Marfan syndrome.2 Open surgical therapy for
proximal aortic disease is well established with excellent
long-term results.3 Marfan syndrome is a disease of the
whole aorta. Prolonged survival after aortic root surgery has
led to a cohort of patients experiencing complications in
the aorta beyond their primary surgical repairs.
Endovascular treatment of type B aortic dissections and
descending thoracic aneurysms has been utilized in non-
Marfan patients. Reports confirm high rates of primary
procedural success with limited morbidity and mortality.4,5
The IRAD (International Registry of Aortic Dissection)
database has reported that 5% of patients undergoing stent
graft deployment for thoracic dissection have Marfan syn-
drome.6 However, the utility of endovascular stent grafting
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Current consensus is that stent grafts should be used
with great caution, if at all, to repair aortic dissection in
patients with Marfan syndrome or other connective tissue
disorders.7 The aorta is prone to further dilation making
any endovascular solution of limited durability.8,9
PATIENTS AND METHODS
We retrospectively reviewed our institutional aortic
database to identify Marfan patients treated at this centre
for aneurysmal dilatation of the thoracic aorta. During a
five year period, seven consecutive patients (six male; mean
age 45.9 10 years, range, 29 to 63 years) presented with
aneurysmal degeneration of the thoracic aorta consequent
to chronic dissection (Table I). A diagnosis of Marfan
syndrome had previously been established in each patient
according to the revised Ghent criteria.10 Patients were not
genotyped for specific variants of Marfan syndrome.
All patients had relative contra-indications to open
thoracic aortic surgery. These included chronic type II
respiratory failure11 secondary to emphysematous changes
and diaphragmatic weakness, pleurodesis for recurrent
spontaneous pneumothoraces, cerebrovascular disease, and
renovascular disease. Five of seven patients were taking
warfarin following prosthetic aortic root/valve replace-
ment. They were appropriately counseled and consented
for endovascular management.
Prospectively gathered data, including demographic,
clinical, and serial imaging of this patient cohort were
analyzed. Morphological characteristics of aneurysms with
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endovascular repair (TEVR) were based on preoperative
contrast-enhanced spiral computed tomography (CT).
Measurements in this report are based on 3mensio (3men-
sio Medical Imaging, Bilthoven, The Netherlands) 3-
dimensional reconstructions generated from the coronal
CT images.
Procedures were performed in the operating roomwith
portable C-arm fluoroscopy (Siemens, Munich, Germany)
or in the angiography suite. Follow-up protocol included
pre-discharge CT scan then serial review in the outpatient
clinic with interval CT angiograms at six weeks, three
months, six months, 12 months, and annually thereafter.
All patients had previously had reconstructive aortic
root surgery and had stable blood pressure with beta-
blockade and/or angiotensin-converting enzyme (ACE)
inhibition. Once appropriately consented, all patients were
managed by TEVR. Patients underwent endovascular ex-
clusion of the aneurysmal aorta utilizing either Talent or
Valiant thoracic aortic stent grafts (Medtronic Vascular,
Santa Rosa, Calif). Six of seven patients required additional
Table I. Patient details
Age Gender
Previous aortic
root revision
Time between root
and stent (yrs)
1 44 M Yes 10
2 48 F Yes 9
3 63 M Yes 4
4 41 M Yes 8
5 55 M Yes 9
6 29 M Yes 3
7 41 M Yes 14
LCCA, Left common carotid artery; LSA, left subclavian artery; RIP, dead.
*Death within 30 days of procedure.
Table II. Procedural detail
Preceding adjunctive bypass
surgery Graft
Number of
stents
Ste
in
a
1 C-C-S* Valiant 3
2 C-C-S* Talent 3
3 — Talent 6
4 3 vessel aortic de-branching Valiant 4
5 Ascending aorta to selective
arch vessels
Valiant 3
6 Ascending aorta to selective
arch vessels  2 vessel
visceral de-branching
Valiant 3
7 Ascending aorta to selective
arch vessels  LCCA to
LSA bypass
Valiant 5
LCCA, Left common carotid artery; LSA, left subclavian artery.
*C-C-S: Right-left carotid-carotid bypass and left carotid-subclavian artery
**Distal landing proximal just proximal to celiac axis; the vessel was not cobypass procedures, including carotid-subclavian, carotid-carotid bypasses, and aortic de-branching, to allow appro-
priate stent-graft deployment (Table II).
It is our policy to consider surgery in patients present-
ing with thoracic aortic dilatation of the arch or descending
thoracic aorta of greater than 55mm, and/or symptomatic.
Covered stent-grafts are deployed to occlude the entry tear
in dissections; grafts are routinely used to obtain coverage
of the entire thoracic aorta to the level of the coeliac axis.
Bare stents are not used. Stent-grafts are oversized by 10%
to 20% at the proximal landing zone. The sizing of the
distal landing zone is more controversial; it remains our
policy in these cases to match the distal landing size to the
true luminal diameter. We believe that preservation of the
left subclavian artery (LSA) is valuable if the morphology of
the dissection allows.12 Additional to this in the perioper-
ative period, mean arterial pressure (MAP) is maintained at
90 mmHg (using inotropes if required) and spinal drains
are sited for 48 hours. Spinal drains are maintained with
maximal CSF (cerebrospinal fluid) drainage of 30 mL/hr
and clamped if drainage exceeds that rate.
All hybrid aortic de-branching was performed prior to
igin of dissection
Extent of dissection
(level) Current situation
CA Aortic bifurcation Alive
CA Aortic bifurcation Alive
id thoracic aorta Aortic bifurcation Alive
A Right common iliac
artery
RIP – Congestive
cardiac failure
ot anastamosis Aortic bifurcation Alive
ot anastamosis Bronchial carina Alive
ot anastamosis Right common iliac
artery
RIP* – Congestive
cardiac failure
ployed
vised
root
Ishimaru
proximal
landing zone18
Stent coverage
(distal landing)
Endoleak
warranting
treatment within
one year
1 Coeliac axis** No
1 Coeliac axis** No
4 Coeliac axis** Type 1b
2 Mid-abdomen No
s 0 Mid-thoracic Type 3
s 0 Mid-abdomen No
s 0 Coeliac axis** —
.
or incorporated.Or
LC
LC
M
LS
Ro
Ro
Ront de
to re
ortic
No
No
No
No
Ye
Ye
Ye
bypassstent deployment in elective cases.
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Seven cases have been treated to date; three urgent
cases for symptomatic aneurysms with increasing back pain,
and four elective for large aneurysms. Mean aortic aneurys-
mal diameter was 64.4 mm (11.2) and mean proximal
landing zone diameter was 36.3 mm (3.3). In all cases,
stent-graft deployment was completed successfully (Table
II). No perioperative neurological complications were en-
countered. A median three (range, two to six) grafts were
deployed. Procedures lasted a mean 160  55 minutes
(range, 120 to 300 minutes). One patient required re-
operation for a groin hematoma at the femoral access vessel.
Thirty-day mortality was 1/7 (14%). The peri-operative
mortality occurred following discharge. The patient was
readmitted to his local hospital where he presented with
pneumonia and severe, irreversible cardiac failure. CT scan-
ning revealed an intact stent-graft with no endoleak or
coarctation.
All patients were enrolled in a graft surveillance pro-
gram on discharge. Median follow-up was 16 months
(range, 3 to 54 months) in the five patients surviving 3
months following primary treatment. Two of six (33%)
patients developed endoleaks requiring treatment within
the first year. One type 1 endoleak and one type 3 endoleak
were managed by additional stent graft deployment with-
out complication (Table II). In neither case, at the primary
surgery, were manufacturers’ recommendations for length
of landing zone or graft overlap compromised.
False lumen thrombosis (FLT) was assessed at each
surveillance CT scan. Five of six patients showed complete
FLT at the level of the stent-grafts during follow-up. One
of six patients demonstrated partial FLT. Only patients
with additional AAA stent grafts thrombosed their false
lumen below the thoracic stents, in the infra-diaphragmatic
aorta (Table III).
All patients demonstrated continued thoracic aortic
dilatation despite stent graft deployment. Crude median
aortic growth rate after graft deployment was 7.2 mm/year
Table III. Changes in aortic morphology and false
lumen thrombosis
Length of
follow-up
(months)
(If 3/12)
Original
aortic
diameter
(cm)
Aorta at
recent
follow-up
(mm)
FLT at
graft
Infra-
diaphragmatic
FLT
1 28 76 92 Yes No
2 54 57 73 Yes No
3 3 48 53 Partial* Yes**
4 — 52 — — —
5 11 60 67 Yes No
6 16 58 66 Yes Yes**
7 — 66 — Yes —
FLT, False lumen thrombosis.
Measurements taken at maximal external aneurysmal aortic diameter.
*Partial FLT- thrombus visible in false lumen, but also persistent flow.
**AAA stent graft in-situ.(range, 3.5 to 19 mm/year).Five of seven of the cohort remain alive and under close
surveillance. One patient died three months following
treatment from congestive cardiac failure.
DISCUSSION
The incidence of Marfan syndrome is around one in 10
000 live births. Progressive aortic dilatation associated with
aortic dissection and rupture is the principal cause of mor-
tality. The excellent surgical results of elective aortic root
replacement are generating an increasing cohort of patients
who present later with an expanding false lumen of the
descending aorta. All patients in this series had undergone
previous aortic root replacement. The median time from
aortic root replacement to presentation with grossly aneu-
rysmal thoracic aorta was nine years (range, 3 to 14 years) in
this series.
After successful aortic root replacement, the dissected
descending aorta remains a source of late complications in
Marfan syndrome.13 Elective aortic root replacement14,15
and thoracoabdominal aneurysm repair16,17 have reported
excellent results in Marfan syndrome patients. In contrast,
open surgical treatment of proximal descending aortic dis-
section is associated with significant morbidity. Early mor-
tality can be up to 20% without absolute protection from
the requirement for further surgery.18 These risks escalate if
aortic arch replacement is required with increasing risks of
stroke.19 Endovascular stent-graft repair would appear an
attractive alternative to open surgery because it is associated
with a reduction in morbidity (particularly stroke and spinal
cord ischemia) and mortality.20
The experience of endovascular management of the
descending thoracic aorta in patients with Marfan syn-
drome remains limited. Small observational studies have
confirmed it to be feasible and relatively safe.20-22 This
series is the largest to date and corroborates these conclu-
sions. It confirms 100% primary technical success and a
30-day mortality of 1/7 (14%). It is not appropriate to
compare the cohort we present with the other three series.
In this series, six of seven cases required stent graft deploy-
ment into the aortic arch (Ishimaru zones 0-223). No cases
in the series reported by Ince et al required coverage of the
left subclavian artery,20 and the series by Baril et al only
included two thoracic aneurysms in Marfan patients.21
Treating the more challenging cases involving the aortic
archmay be an explanation of our relative greater morbidity
and mortality.
Long-term outcome of management of chronic dissec-
tions in the general population has been shown to be
related to false lumen thrombosis. Continued false lumen
patency is associated with increased rupture risk24 and
partial FLT has been reported as an independent predictor
of mortality.25 FLT occurred in five of six patients and
partial FLT in one of six patients. Despite thrombosing the
false lumen, the aortas continued to dilate. This highlights
the difficulty of managing aortic dissection in patients with
connective tissue disorders. This study confirms that pa-
tients appear to continue to dilate their aorta despite cov-
erage of the primary entry tear and false lumen thrombosis.
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appear to be associated with graft type. Successful exclusion
of the false lumen and associated thrombosis should confer
protection against rupture. How and why the aorta contin-
ues to dilate and the clinical relevance of this finding is yet
to be elucidated.
It has been proposed that once aortic dissection occurs
in patients with Marfan syndrome, an unfavorable “natu-
ral” history begins.26 This proceeds through surgery, revi-
sion surgery, and eventual premature death. A significantly
better outcome is observed if aortic dissection can be pre-
vented by elective aortic root surgery on the non-dissected
aorta.
It is our philosophy, when possible, to target stent
deployment into a replaced aortic segment; as was possible
in three of seven cases in this series. This provides a stable
platform that should reduce proximal type 1 endoleaks. A
key challenge of endovascular treatment of thoracic aneu-
rysms is the variable morphology of the aortic arch. This
challenge is reduced when deploying into a prosthetic
proximal landing zone, such as an elephant trunk. In
Marfan patients there will be continued dilatation of the
distal thoracic and abdominal aorta. Supplemental stent-
grafting can be performed, and where necessary hybrid
extra-anatomical bypass or branch/fenestrated stent-graft
technology to maintain aortic branch perfusion may be
considered.
Aortic disease in Marfan syndrome will often require
repeated interventions and multiple surgeries, regardless of
the modality utilized for repair.27 Geisbusch et al reported
three of six (50%) of the chronic dissection cases for aortic
dissection continued to dilate despite endograft exclusion
of the aneurysm.22 In our series, all patients’ thoracic aortas
continued to dilate and no abdominal false lumens throm-
bosed. The significance of aortic dilatation in the presence
of false lumen thrombosis is difficult to explain and longi-
tudinal follow up will be required to define whether false
lumen thrombosis confers protection from aortic rupture in
this setting.
This series demonstrates the uncertainty surrounding
the use of endovascular techniques in patients with Marfan
syndrome and chronic dissections of the distal aorta. The
technique may confer protection from rupture through false
lumen thrombosis, although this remains to be proven. En-
dovascular repair may offer a viable treatment option in
patients who have contraindications to open surgery, but
longer follow up of more patients is required to define the
place of this therapy.
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